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ABSTRACT The favorable treatment outcome rate for multidrug-resistant tuberculo-
sis (MDR-TB) is only 54%, and therefore new drug regimens are urgently needed. In
this study, we evaluated the activity of the combination of moxiﬂoxacin and lin-
ezolid as a possible new MDR-TB regimen in a murine TB model and the value of
the addition of the efﬂux pump inhibitor verapamil to this backbone. BALB/c mice
were infected with drug-sensitive Mycobacterium tuberculosis and were treated with
human-equivalent doses of moxiﬂoxacin (200 mg/kg of body weight) and linezolid
(100 mg/kg) with or without verapamil (12.5 mg/kg) for 12 weeks. Pharmacokinetic
parameters were collected during treatment at the steady state. After 12 weeks of
treatment, a statistically signiﬁcant decline in mycobacterial load in the lungs was
observed with the moxiﬂoxacin-linezolid regimen with and without verapamil (5.9
and 5.0 log CFU, respectively), but sterilization was not achieved yet. The spleens of
all mice were culture negative after 12 weeks of treatment with both treatment mo-
dalities, and the addition of verapamil caused a signiﬁcant reduction in relapse
(14/14 positive spleens without versus 9/15 with verapamil, P  0.017). In conclu-
sion, treatment with a combination regimen of moxiﬂoxacin and linezolid showed a
strong decline in mycobacterial load in the mice. The addition of verapamil to this
backbone had a modest additional effect in terms of reducing mycobacterial load in
the lung as well as reducing the spleen relapse rate. These results warrant further
studies on the role of efﬂux pump inhibition in improving the efﬁcacy of MDR-TB
backbone regimens.
KEYWORDS Mycobacterium tuberculosis, efﬂux pump inhibitor, linezolid,
moxiﬂoxacin, verapamil
Tuberculosis (TB) is the leading cause of death from infectious disease worldwide. Anestimated 1.7 million people died due to this disease in 2016, and an estimated 10.4
million people fell ill in the same year (1). Drug resistance remains a problem for the
treatment of TB; an estimated 4% of the new TB cases and 19% of previously treated
TB cases had rifampin-resistant or multidrug-resistant TB (MDR-TB) (1). Currently,
patients with MDR-TB need to undergo up to 2 years of treatment, which is often
associated with toxic side effects, while only 54% of patients are being cured (1). Novel
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treatment regimens that are more effective, short, and safe need to be developed to
treat this devastating disease.
In order to increase the treatment efﬁcacy in the short term, we focused in this study
on drugs which are already registered for use. Fluoroquinolones, in particular, moxi-
ﬂoxacin (MXF) and levoﬂoxacin, are considered to be among the most important
groups of drugs in the treatment of MDR-TB (2, 3). In murine TB models moxiﬂoxacin
was found to be the most bactericidal of all quinolones. It also showed good activity
against rifampin-tolerant TB and MDR-TB in different mouse TB models (4, 5). Further-
more, a randomized controlled trial showed promising success rates in patients with
MDR-TB treated with a regimen that included moxiﬂoxacin (6). Therefore, moxiﬂoxacin
is now recommended by the World Health Organization (WHO) in their most recent
guideline outlining a shorter MDR-TB regimen (8 to 12 months instead of at least 18
months of treatment) for patients who were not previously treated with second-line
drugs (7).
In the current WHO treatment guideline, linezolid (LZD) (an oxazolidinone) is
classiﬁed as a core second-line agent (group C) (7). In vitro and in vivo studies showed
good activity of linezolid against multiple MDR-TB strains (4, 8), and a systematic review
and meta-analysis of patients treated with linezolid-containing MDR-TB and extensively
drug-resistant TB (XDR-TB) regimens showed promising results (9). Furthermore, a
meta-analysis of MDR-TB patients treated with (at that time) group 5 drugs showed that
the use of linezolid increased the probability of a successful treatment outcome in this
group by 57% (10). Ongoing studies include an evaluation of linezolid combined with
bedaquiline and pretomanid in a short (6-month) trial of treatment for XDR-TB (Nix-TB)
(11) and a phase 3 study evaluating various doses and treatment durations of linezolid,
bedaquiline, and pretomanid in MDR-TB and XDR-TB patients (ZeNix trial; ClinicalTrials
registration no. NCT03086486).
Although the effectiveness of moxiﬂoxacin and linezolid appears to be promising,
the emergence of resistance to both drugs is a problem. There is accumulating
evidence supporting a role for mycobacterial efﬂux pumps in the extrusion of TB drugs
and emergence of drug resistance to both ﬂuoroquinolones and oxazolidinones (12,
13). Thus, inactivation of these mycobacterial efﬂux pumps by efﬂux pump inhibitors
(EPIs) could be a valuable strategy to increase intrabacterial drug concentrations and
reduce the emergence of drug resistance (14).
Verapamil was the ﬁrst discovered inhibitor of P-glycoprotein-mediated drug efﬂux
(15) and was shown to be able to increase the accumulation of P-glycoprotein substrate
drugs in macrophages (16). Another study showed that macrophage-induced tolerance
of moxiﬂoxacin could be reversed upon exposure to verapamil (12). Furthermore,
verapamil not only affects macrophage efﬂux pumps but also has been identiﬁed as an
inhibitor of Mycobacterium tuberculosis efﬂux systems (17–20). Besides, verapamil is
widely used for the treatment of cardiovascular diseases, in contrast to several other
EPIs which are not registered yet or have been withdrawn from the market due to
severe side effects (21–23).
In the present study, we evaluated the value of the addition of verapamil to a
backbone of moxiﬂoxacin and linezolid. We assessed the efﬁcacy of this regimen in
BALB/c mice infected with a M. tuberculosis strain of the Beijing genotype and evalu-
ated the pharmacokinetic proﬁles of drugs in this regimen.
RESULTS
Mycobacterial load (efﬁcacy) assessment. Both moxiﬂoxacin plus linezolid (group
1) and moxiﬂoxacin plus linezolid plus verapamil (group 2) combination treatments
were well tolerated, although mice showed mild distress during the ﬁrst 3 weeks of
treatment in both groups.
The mycobacterial load in lungs and spleen during 12 weeks of treatment and after
a 12-week posttreatment period is presented in Fig. 1. The median total amount of
mycobacteria in the lungs at start of treatment was 8.18 log CFU (interquartile range
[IQR], 7.96 to 8.19). During the 12 weeks of treatment, the mycobacterial load in the
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lungs declined, with 5.0 log CFU in group 1 (P  0.0001) and with 5.9 log CFU in group
2 (P  0.0001) compared to the start of treatment. No signiﬁcant difference between
group 1 and group 2 was observed at this time point. No sterilization of the lungs was
achieved with either of the treatment modalities. As a result, no assessment of relapse
in lung tissue was possible. In contrast, the spleens of all mice were culture negative
after 12 weeks of treatment. The addition of verapamil was associated with a signiﬁcant
FIG 1 Mycobacterial load in lung (a) and spleen (b) expressed as median  range (error bars) of the CFU
per organ, at weeks 2, 6, 10, and 14 and at 12 weeks posttreatment (week 26). Gray bars represent mice
treated with moxiﬂoxacin and linezolid; striped bars represent mice treated with moxiﬂoxacin, linezolid,
and verapamil. Numbers above bars represent the numbers of culture-positive mice among the total
numbers of mice at that time point. Signiﬁcance is noted as follows: **, P  0.0001; *, P  0.05. †, 1 mouse
became moribund before the planned dissection; ^, 1 measurement is missing due to a contaminated
plate. LZD, linezolid; MXF, moxiﬂoxacin; VPM, verapamil.
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reduction in relapse after 3 months of treatment, as measured in the spleen (9/15
culture-positive samples in group 2 versus 14/14 in group 1, P  0.017).
Pharmacokinetic evaluation. Plasma concentration-time proﬁles and pharmacoki-
netic parameters of the study drugs are shown in Fig. 2 and Table 1.
The total exposure to moxiﬂoxacin was 53% higher in the mice that received
verapamil; also, the peak concentration (Cmax) was 44% higher with addition of
verapamil (9.5 versus 6.6 mg/liter). In contrast, the area under the plasma
concentration-time curve from 0 to 24 h (AUC0–24) of linezolid was slightly (17%) lower
FIG 2 Moxiﬂoxacin (a), linezolid (b), and (nor)verapamil (c) plasma concentration-time proﬁles at steady state following an oral dose of
200 mg/kg moxiﬂoxacin, 100 mg/kg linezolid, and/or 12.5 mg/kg verapamil inM. tuberculosis-infected BALB/c mice. Plasma concentrations
are plotted as means  standard errors of the means (SEM) of results from three mice per study drug per time point. LZD, linezolid; MXF,
moxiﬂoxacin; VPM, verapamil; nor-VPM, norverapamil.
TABLE 1 Pharmacokinetic parameters at steady state of moxiﬂoxacin and linezolid and













MXF ( LZD) 200 30.0 6.6 0.15 0.92 4.3
MXF ( LZD  VPM) 200 46.0 9.5 0.10 0.43 3.1
LZD ( MXF) 100 215 32.7 0.010 0.028 1.9
LZD ( MXF  VPM) 100 179 31.3 0.012 0.035 1.9
VPM ( MXF  LZD) 12.5 2,670b 365b 0.00010 0.00067 4.5
nor-VPM ( MXF  LZD) NA 1,387b 149b NA NA NA
aPharmacokinetic parameters are based on 8 time points; concentrations at each time point are based on
plasma samples of 3 mice. AUC0–, area under the plasma concentration-time curve within the dosing
interval; Cl, clearance; Cmax, maximum plasma concentration; F, bioavailability; LZD, linezolid; MXF,
moxiﬂoxacin; NA, not applicable; nor-VPM, norverapamil; t1/2, half-life; V, volume of distribution; VPM,
verapamil.
bFor verapamil and norverapamil, AUC0– and Cmax are expressed in micrograms per liter per hour and
micrograms per liter, respectively.
Pieterman et al. Antimicrobial Agents and Chemotherapy











in mice that received verapamil, whereas the linezolid peak concentrations in the two
groups were nearly identical (31.3 and 32.7 mg/liter). The total exposures of verapamil
and its active metabolite norverapamil were 2,670 g/liter · h and 1,387 g/liter · h,
respectively, with Cmax levels of 365 g/liter and 149 g/liter, respectively.
DISCUSSION
To our knowledge, this was the ﬁrst study evaluating whether verapamil could
increase the treatment efﬁcacy of a combination regimen consisting of moxiﬂoxacin
and linezolid in a murine TB model. Previous studies examining the additional value of
verapamil in the treatment of TB focused on combining verapamil with only one drug
or with the standard drug regimen against drug-sensitive M. tuberculosis (24–26),
whereas our study focused on improving a new two-drug MDR-TB backbone.
In our study, the combination of moxiﬂoxacin and linezolid achieved a strong
reduction in mycobacterial load in the lungs after 3 months of treatment and the
mycobacterial load in the spleen was undetectable at that time point. Although
multiple randomized controlled trials showed promising treatment outcomes of
MDR-TB regimens containing linezolid or moxiﬂoxacin, with success rates of approxi-
mately 80%, limited data are available on the combination of the two drugs in humans
(6, 27). Most studies on MDR-TB regimens containing linezolid in humans were per-
formed either in the presence of moxiﬂoxacin resistance or with linezolid added to a
wide variety of different TB drugs (28, 29). However, previous in vitro studies showed
that combining the two drugs resulted in synergistic as well as indifferent or antago-
nistic effects, which has been postulated to be strain dependent (30, 31).
In the present study, the addition of verapamil did not signiﬁcantly increase the
treatment efﬁcacy of the moxiﬂoxacin-linezolid backbone in terms of treatment out-
come at 3 months of treatment. However, we did observe a modest additional decline
in mycobacterial load in the lungs at the end of treatment as well as a signiﬁcantly
reduced relapse rate in the spleen with the addition of verapamil. Several other studies
showed promising effects of the use of verapamil in combination with different anti-TB
drugs. For example, Gupta et al. showed that verapamil could increase the treatment
efﬁcacy of a standard TB drug regimen consisting of rifampin, isoniazid, and pyrazin-
amide in mice infected with drug-sensitive M. tuberculosis (24). Similarly, it was shown
for the new TB drug bedaquiline that subinhibitory dosing of bedaquiline in a murine
drug-sensitive TB model could become as effective as regular dosing after the addition
of verapamil (25). Both murine TB studies showed a signiﬁcant difference of1 log CFU
between regimens with and without verapamil at different time points (24, 25). This
observation was comparable to our ﬁndings in the lung tissue. Also in line with the
results of our study showing a reduced relapse rate in the spleen, Gupta et al. showed
reduced relapse rates with the addition of verapamil to the standard TB drug regimen
(24). However, since all mice in our study were still culture positive in the lungs, it is
difﬁcult to assess the clinical value of this observation. Therefore, it would be worth-
while to evaluate the efﬁcacy of this regimen in a future study for an extended period
of time, in order to assess whether sterilization could be achieved in all tissues. In that
case, relapse reduction mediated by verapamil, as observed by Gupta et al. (24), might
possibly be replicated and might support the idea of the value of the addition of
verapamil to this backbone. Interestingly, our previous in vitro study did not show any
additional effect of verapamil on the activity of the moxiﬂoxacin-linezolid combination
(32). It could be hypothesized that the effect observed in the present study was
mediated through the effects of verapamil on the efﬂux pumps present in macro-
phages. Such an effect was shown by Adams et al. in a TB macrophage model where
the addition of verapamil reduced tolerance to multiple TB drugs (12).
In order to evaluate the inﬂuence of verapamil on the pharmacokinetics of our
backbone, we compared the pharmacokinetic parameters of moxiﬂoxacin and linezolid
with and without verapamil. We observed that the total exposure to moxiﬂoxacin was
approximately 53% higher upon the addition of verapamil. These results were compa-
rable to the observations of Xu et al., who found a 46% increased AUC of bedaquiline
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after addition of verapamil (26). The authors postulated that the increased effectivity of
bedaquiline was likely due to the increased bioavailability mediated through an effect
of verapamil on mammalian drug transporters rather than to inhibiting efﬂux pumps
present in mycobacteria and/or macrophages (26). Since moxiﬂoxacin is subject to
P-glycoprotein-mediated efﬂux (33), the increased AUC could perhaps be ascribed to
the inhibition of P-glycoprotein-mediated drug efﬂux at the site of the intestines of the
mice (34) and might have been the cause of the modest decline in CFU in the lungs.
Besides, it is unlikely that the increased effectivity of the backbone after verapamil
addition was due to the antimycobacterial effect of verapamil only, since in our
previous in vitro study verapamil showed (modest) activity only at concentrations of
64 mg/liter (32). Moreover, other in vivo studies also showed no effect of the
verapamil for single drug exposures (20, 26).
The results of our pharmacokinetic analyses conﬁrm that drug exposures in this
murine study resemble those achieved in humans. Total exposures to moxiﬂoxacin
(AUC within the dosing interval [AUC0–t], 30 mg/liter · h) were comparable with the
range of exposures found in humans (AUC0–24, 25 to 29 mg/liter · h), which were
obtained with the recommended 400 mg of moxiﬂoxacin orally (35, 36). Similarly, total
exposures to linezolid in our study were comparable to AUC0–12 values found in
pharmacokinetic studies in humans after an oral intake of 600 mg linezolid twice daily
(AUC0–12, 108 to 146 mg/liter · h) (37, 38). Verapamil exposure in our study mimicked
the range observed in humans, namely, an AUC0–24 of 3,253 g/liter · h after daily oral
intake of 240 mg of slow-release verapamil (39) and an AUC0–8 of 1,999 g/liter · h after
thrice-daily oral intake of 120 mg immediate-release verapamil with a norverapamil
total exposure of 2,312 g/liter · h (40). Although total exposures were comparable to
human exposures, the Cmax levels of moxiﬂoxacin and linezolid in this study were
higher than those seen in humans (6.6 mg/liter versus 3.9 mg/liter and 32.7 mg/liter
versus 20.4 mg/liter, respectively) (36, 37). Since the AUC/MIC ratio is considered to be
the driver of efﬁcacy for moxiﬂoxacin and linezolid (41, 42) and the moxiﬂoxacin
Cmax/MIC ratio showed a poor correlation in efﬁcacy in BALB/c mice (42), we assumed
that this has a limited effect on the translational value.
In conclusion, the present study in mice showed a strong and steady CFU decline
with the combination of moxiﬂoxacin and linezolid. The addition of verapamil had a
modest additional effect in terms of reducing mycobacterial load in the lung after 3
months of treatment as well as in terms of reducing spleen relapse rates. These results
warrant further studies on the role of efﬂux pump inhibition in improving the efﬁcacy
of MDR-TB backbone regimens.
MATERIALS AND METHODS
Animals. Female BALB/c mice that were speciﬁed to be free of pathogens were obtained from Charles
River (Les Oncins, France). At the start of the experiments, animals were 13 to 15 weeks old and weighed 20
to 25 g. Experimental protocols adhered to the rules speciﬁed in the Dutch Animal Experimentation Act and
were in concordance with EU animal directive 2010/63/EU. The Institutional Animal Care and Use Committee
of the Erasmus Medical Centre (MC) approved the present protocols (117-12-14).
Bacterial strain. The M. tuberculosis Beijing VN 2002-1585 genotype strain (43), with a moxiﬂoxacin
MIC of 0.25 mg/liter and a linezolid MIC of 1 mg/liter, was used (43, 44). MICs were determined according
to Clinical and Laboratory Standards Institute (CLSI) standards (45).
Experimental setup. For treatment efﬁcacy and pharmacokinetic analyses, a total of 99 mice (51
mice for efﬁcacy assessment and 48 mice for pharmacokinetic analysis) were infected withM. tuberculosis
as described previously (46). In short, mice under anesthesia were infected by intratracheal instillation
with a suspension (40 l) containing 2.9  105 CFU (2.5  105 to 3.2  105) of M. tuberculosis, followed
by inhalation to ensure the formation of a bilateral TB infection (46). Two weeks after infection, three
mice were used as controls to determine infection efﬁcacy and reproducibility over time. A total
population of 48 mice was divided in two combination therapy groups; the ﬁrst group received 200 mg
moxiﬂoxacin/kg of body weight (Bayer, Leverkusen, Germany) plus 100 mg/kg linezolid (Sigma-Aldrich,
Zwijndrecht, the Netherlands), and the second group received the same backbone in combination with
12.5 mg/kg verapamil (Sigma-Aldrich, Zwijndrecht, the Netherlands). Mice were treated for 12 weeks.
After 12 weeks of treatment, 30 mice (n  15 per group) were kept for another 12 weeks without
treatment to assess relapse in lung and spleen. Selected doses were chosen based on previous in vivo
mouse studies (25, 47, 48). Dry powder moxiﬂoxacin was dissolved in distilled water plus 0.05% agarose
using a mortar and pestle. Dry powder linezolid was dissolved in distilled water and added to the
moxiﬂoxacin suspension. Verapamil was dissolved in distilled water and added to the moxiﬂoxacin-plus-
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linezolid suspension. Drugs were administered orally 5 times per week, using a feeding cannula, in a total
volume of 0.2 ml per day.
Mycobacterial load (efﬁcacy) assessment. A total of 51 of the infected mice receiving treatment
were sacriﬁced at the start of therapy or after 4, 8, and 12 weeks of therapy (n  3 per time point per
regimen) and at 12 weeks posttreatment to assess relapse (n  15 per regimen). Relapse was deﬁned as
the presence of 1 CFU on a culture plate, observed after complete sterilization at 12 weeks of
treatment. To prevent carryover of TB drugs, therapy was stopped 72 h before the mice sacriﬁced and
activated charcoal (0.4%) was added to the culture media. The lungs and spleen were removed
aseptically and homogenized separately in M-tubes using a gentleMACS Octo Dissociator and the RNA
program (Miltenyi Biotec BV, Leiden, the Netherlands) in 2 ml phosphate-buffered saline. Serial 10-fold
dilutions were performed with each tissue homogenate, and samples of 200 l were cultured on
drug-free 7H10 Middlebrook agar containing activated charcoal and incubated for 28 days at 37°C with
5% CO2 to perform colony counting.
Pharmacokinetic analyses. Pharmacokinetic analyses were performed at the steady state after 4
weeks of treatment in the other population of the infected mice (n  48). These mice were sacriﬁced by
CO2 exposure, and blood samples were taken via cardiac puncture at 0.25, 0.5, 1, 1.5, 3, 5, 10, and 24 h
after the dose. Three animals were euthanized for each of the eight sampling time points in each group
(n  48 total). Blood was collected in microcentrifuge tubes containing EDTA. Subsequently, blood was
centrifuged at 10,000  g for 5 min to obtain plasma, which was stored at 80°C upon analysis.
Moxiﬂoxacin concentrations in plasma were analyzed with a liquid chromatography-tandem mass
spectrometry (LC-MS/MS) assay, validated for human plasma, at the University Medical Center Groningen,
the Netherlands (49). Cross-validation of the assay for human plasma to murine plasma was performed
by comparing responses of 5-fold measurements of quality control (QC) moxiﬂoxacin samples (at
concentrations of 0.5, 2.5, and 5.0 mg/liter) in human plasma with those determined in murine plasma
after analysis of all samples with the LC-MS/MS assay for human plasma. The accuracy of measurement
of murine samples with the assay for human samples was between 88% and 97%, and the within-run
coefﬁcient of variation (CV) amounted to 4.0% to 6.2%.
Linezolid concentrations in plasma were analyzed by a validated high-performance liquid chromatography-
tandemmass spectrometry (LC-MS/MS) assay at the University Medical Center Groningen, Groningen, the
Netherlands (50). The assay accuracy was 96.3% to 108.5%, the within-run CV ranged from 2.5% to 7.1%,
and the lower limit of quantitation (LLOQ) was 0.05 mg/liter. Cross-validation between human and
murine plasma matrices was performed by comparing the responses seen with three QC linezolid
concentrations (0.5, 15, and 30 mg/liter in 5-fold) in human plasma with those in murine plasma. The
accuracy of murine plasma measurements relative to human plasma measurements was between 101%
and 114%, with a within-run CV of 1.7% to 2.6%.
Verapamil and norverapamil concentrations were analyzed on a Thermo Fisher (San Jose, CA, USA)
triple-quadrupole LC-MS/MS system with a Finnigan Surveyor LC pump and a Finnigan Surveyor
autosampler. The mobile phase consisted of an aqueous buffer (containing ammonium acetate at 5
g/liter, acetic acid at 35 ml/liter, and triﬂuoroacetic anhydride at 2 ml/liter water), water, and acetonitrile
and had a ﬂow rate of 0.3 ml/min. Samples were prepared by the use of 100 l serum or plasma and 750
l precipitation reagent (mixture of methanol and acetonitrile [4:21 {vol/vol}]) containing cyanoi-
mipramin as an internal standard, subjected to vortex mixing for 1 min, and subsequently centrifuged
at 11,000  g for 5 min. From the clear upper layer, 5 l was injected onto the LC-MS/MS system. A
Finnigan TSQ Quantum Discovery mass selective detector was used in electrospray positive ionization
mode and performed selected reaction monitoring. The mass transitions for verapamil were 455.3 m/z
to 165.1 m/z and for norverapamil were 441.2 m/z to 165.0 m/z; a scan width of 0.5 m/z was used. The
calibration curves were linear within the concentration range of 18 to 1,800 g/liter for verapamil and
19 to 1,900 g/liter for norverapamil, with correlation coefﬁcients (R2) of 0.997 and 0.999, respectively.
This method was precise and accurate; within-day precision ranged between 1.0% and 5.5% for
verapamil and between 1.6% and 5.9% for norverapamil, and between-day precision ranged from 1.5%
to 3.1% for verapamil and 0.0% to 1.2% for norverapamil. The calculated accuracy ranged from 1.8% to
4.5% for verapamil and 0.2% to 2.0% for norverapamil.
All measured concentrations represent total (i.e., protein-bound plus unbound) drug concentrations.
Pharmacokinetic parameters were assessed using standard noncompartmental methods in Phoenix
WinNonlin version 6.4 (Pharsight Corporation), as described previously (51).
Statistical analysis. CFU counts were log10 transformed before analysis. Group mean CFU counts at
various time points after start of treatment were compared using one-way analysis of variance with a
Bonferroni multiple-comparison test. Proportions of mice relapsing were compared using Fisher’s exact
test. In a previous study, we observed that a sample size of 3 or more mice is sufﬁcient to achieve 100%
power to detect a statistically signiﬁcant difference in potency of 50% between different treatments (52).
The statistical signiﬁcance level adopted was a P value of 0.05. Analyses were performed using Prism
5 (GraphPad Software, San Diego, CA, USA).
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